59.54 F
New York, US
March 11, 2026
PreetNama
English News

NATO chief warns of high price if troops leave Afghanistan

NATO Secretary-General Jens Stoltenberg warned Tuesday that the military organization could pay a heavy price for leaving Afghanistan too early, after a U.S. official said President Donald Trump is expected to withdraw a significant number of American troops from Afghanistan in the coming weeks.

“We now face a difficult decision. We have been in Afghanistan for almost 20 years, and no NATO ally wants to stay any longer than necessary. But at the same time, the price for leaving too soon or in an uncoordinated way could be very high,” Stoltenberg said in a statement.

He said the conflict-ravaged country “risks becoming once again a platform for international terrorists to plan and organize attacks on our homelands. And ISIS (Islamic State) could rebuild in Afghanistan the terror caliphate it lost in Syria and Iraq.”

The US decision comes just days after Trump installed a new slate of loyalists in top Pentagon positions who share his frustration with the continued troop presence in the war zones. The expected plans would leave 2,500 troops in Afghanistan after mid-January.

US officials said military leaders were told over the weekend about the planned withdrawal and that an executive order is in the works but has not yet been delivered to commanders.

NATO took charge of the international security effort in Afghanistan in 2003, two years after a U.S-led coalition ousted the Taliban for harboring former al-Qaida leader Osama bin Laden. In 2014, it began to train and advise Afghan security forces, but has gradually pulled troops out in line with a US-brokered peace deal.

NATO relies heavily on the US armed forces to operate in Afghanistan.

Related posts

Imran Khan again calls for US mediation in Kashmir

On Punjab

This restaurant chain founded by a Delhi man plans to sell Japanese curry to India

On Punjab

he plans for AstraZeneca’s new headquarters and large R&D campus in Cambridge were unveiled in 2013, but its costs and timeframe have exceeded the initial estimate of 330 million pounds and an aimed completion date of 2016. AstraZeneca, which has a large portfolio of treatments for diseases such as cancer, heart disease and diabetes, said the centre would support research into specialised medicines and next-generation therapeutics, including gene-editing and cell therapies. “We will have advances that could come to the clinic in the next three, four years, that can lead to really effective new drugs in various aspects of treating cancer,” Dr Susan Galbraith, AstraZeneca’s executive vice president, Oncology Research & Development, told Reuters in an interview. “I’m very optimistic about the fact that we can make a big difference to this disease in the coming decade”.

On Punjab